Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy ...
First-line zongertinib showed antitumor activity in treatment-naive patients with advanced or metastatic HER2-mutant ...
Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy ...
Isolated antineutrophil cytoplasmic antibody-associated interstitial lung disease is an increasingly recognized fibrotic ILD phenotype.
Allrock Bio has dosed the first participants in a small clinical trial testing ROC-101 as an add-on treatment for pulmonary ...
The initial public offering (IPO) market showed signs of life for the first time in more than a month as Boston-based Avalyn ...
SAQE, a tool with over 90% accuracy for diagnosing Hypersensitivity Pneumonitis. This lung condition, prevalent in South Asia, leads to fibrosis. The tool uses a questionnaire to assess environmental ...
MedPage Today on MSN
Encouraging activity in poor-risk endometrial cancer with HER2-targeted novel drug
Almost half of patients with recurrent/metastatic disease responded to trastuzumab pamirte ...
A new study suggests that COVID-19 may slightly increase the risk of lung cancer by triggering a biological chain reaction in ...
Avalyn Pharma's IPO aims to fund inhaled IPF therapies as AP01 shows positive Phase II results. Read the full analysis here.
Backed by Novo Holdings and multiple other prominent investors, the biotech is developing what it’s positioning as superior ...
Specific combinations of CT imaging features rather than individual findings alone may improve the accuracy of identifying ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results